Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

A. Drilon; B. Besse; D. R. Camidge; S. H.I. Ou; S. M. Gadgeel; M. L. Johnson; A. Calles; M. J. de Miguel; A. I. Spira; E. Felip; G. Lopes; A. J. van der Wekken; Y. Y. Elamin; J. Green; Y. Sun; J. Soglia; V. W. Zhu; J. J. Lin

doi:10.1016/S0959-8049(22)00821-8

Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

A. Drilon, B. Besse, D. R. Camidge, S. H.I. Ou, S. M. Gadgeel, M. L. Johnson, A. Calles, M. J. de Miguel, A. I. Spira, E. Felip, G. Lopes, A. J. van der Wekken, Y. Y. Elamin, J. Green, Y. Sun, J. Soglia, V. W. Zhu, J. J. Lin

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

6 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	S6-S7
journal	European Journal of Cancer
Volume	174
Les DOIs	https://doi.org/10.1016/S0959-8049(22)00821-8
état	Publié - 1 oct. 2022

Accès au document

10.1016/S0959-8049(22)00821-8

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Drilon, A., Besse, B., Camidge, D. R., Ou, S. H. I., Gadgeel, S. M., Johnson, M. L., Calles, A., de Miguel, M. J., Spira, A. I., Felip, E., Lopes, G., van der Wekken, A. J., Elamin, Y. Y., Green, J., Sun, Y., Soglia, J., Zhu, V. W., & Lin, J. J. (2022). Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. European Journal of Cancer, 174, S6-S7. https://doi.org/10.1016/S0959-8049(22)00821-8

@article{1f308685a95244bfb97b48023b343d04,

title = "Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors",

author = "A. Drilon and B. Besse and Camidge, {D. R.} and Ou, {S. H.I.} and Gadgeel, {S. M.} and Johnson, {M. L.} and A. Calles and {de Miguel}, {M. J.} and Spira, {A. I.} and E. Felip and G. Lopes and {van der Wekken}, {A. J.} and Elamin, {Y. Y.} and J. Green and Y. Sun and J. Soglia and Zhu, {V. W.} and Lin, {J. J.}",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/S0959-8049(22)00821-8",

language = "English",

volume = "174",

pages = "S6--S7",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Drilon, A, Besse, B, Camidge, DR, Ou, SHI, Gadgeel, SM, Johnson, ML, Calles, A, de Miguel, MJ, Spira, AI, Felip, E, Lopes, G, van der Wekken, AJ, Elamin, YY, Green, J, Sun, Y, Soglia, J, Zhu, VW & Lin, JJ 2022, 'Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors', European Journal of Cancer, VOL. 174, p. S6-S7. https://doi.org/10.1016/S0959-8049(22)00821-8

TY - JOUR

T1 - Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

AU - Drilon, A.

AU - Besse, B.

AU - Camidge, D. R.

AU - Ou, S. H.I.

AU - Gadgeel, S. M.

AU - Johnson, M. L.

AU - Calles, A.

AU - de Miguel, M. J.

AU - Spira, A. I.

AU - Felip, E.

AU - Lopes, G.

AU - van der Wekken, A. J.

AU - Elamin, Y. Y.

AU - Green, J.

AU - Sun, Y.

AU - Soglia, J.

AU - Zhu, V. W.

AU - Lin, J. J.

PY - 2022/10/1

Y1 - 2022/10/1

UR - http://www.scopus.com/inward/record.url?scp=85140461418&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00821-8

DO - 10.1016/S0959-8049(22)00821-8

M3 - Article

AN - SCOPUS:85140461418

SN - 0959-8049

VL - 174

SP - S6-S7

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -